SURMOUNT-1 Trial Results (Published in New England Journal of Medicine): According to the SURMOUNT-1 clinical trial enrolling 2,539 participants, tirzepatide achieved the following mean weight reductions at 72 weeks: 5 mg dose: 16.0% mean weight loss (approximately 35 lbs or 16 kg) 10 mg dose: 21.4% mean weight loss (approximately 49 lbs or 22 kg) 15 mg dose: 22.5% mean weight loss (approximately 52 lbs or 24 kg) Placebo: 2.4% mean weight loss (approximately 5 lbs or 2 kg) According to the trial data, 89% to 96% of participants taking tirzepatide at the 10 mg and 15 mg doses achieved at least 5% body weight reduction, compared to 28% of those taking placebo
1 2 3 4 "Does melanotan injections (TAN JAB) cause melanoma
Muscle Nerve (2005) 32(3):3579
Reference data comes from, among others: from the works of Coskun et al
Mounjaro tackles this at the root by improving insulin sensitivity and promoting weight loss
This approach ensures that GLP-1 treatment is both safe and effective based on individual needs, taking into account other factors such as medical conditions, medications, and possible side effects